• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC. Read More

Breaking Down The Use of Rina-S in Advanced Ovarian Cancer

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer. Read More

TLX101 Demonstrated Efficacy in Recurrent High-Grade Glioma

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study. Read More

15% of U.S. Cancer Patients Are Active Smokers at Time of Diagnosis

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles The addition of smoking status to the National Cancer Database might inform more effective treatment for smokers with cancer. Read More

Lung cancer screening can’t leave anyone in the UK behind

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: Cancer Research UK – Cancer News The post Lung cancer screening can’t leave anyone in the UK behind appeared first on Cancer Research UK – Cancer News. Read More

We want every scientist to thrive in cancer research

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: Cancer Research UK – Cancer News The post We want every scientist to thrive in cancer research appeared first on Cancer Research UK – Cancer News. Read More
« Older Entries
Next Entries »

Recent Content

  • Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
  • FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
  • FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
  • Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways
  • Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
  • What Should Patients with Multiple Myeloma Know After ASCO 2025?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT